Cargando…

Thrombotic Complications Associated with Immune Checkpoint Inhibitors

SIMPLE SUMMARY: Patients with cancer commonly develop blood clots, which can cause issues including hospitalizations and complications and can affect cancer treatments. Cancer therapies can be one of the reasons for blood clots. A type of cancer therapy called “immune checkpoint inhibitors” has been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Tzu-Fei, Khorana, Alok A., Carrier, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469452/ https://www.ncbi.nlm.nih.gov/pubmed/34572833 http://dx.doi.org/10.3390/cancers13184606

Ejemplares similares

Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management
por: Wang, Tzu-Fei, et al.
Publicado: (2023)

Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment—A report from ICTHIC 2021
por: Falanga, Anna, et al.
Publicado: (2022)

Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival
por: Sussman, Tamara A, et al.
Publicado: (2021)

Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer
por: Khorana, Alok A, et al.
Publicado: (2023)

Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors
por: Youssef, Alexey, et al.
Publicado: (2018)

How we treat endocrine complications of immune checkpoint inhibitors
por: Paschou, S.A., et al.
Publicado: (2021)

Thrombotic Complications in Patients with Immune-Mediated Hemolysis
por: Capecchi, Marco, et al.
Publicado: (2021)

Guidance for the prevention and treatment of cancer-associated venous thromboembolism
por: Khorana, Alok A., et al.
Publicado: (2016)

Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019)

Hematologic complications of immune checkpoint inhibitors
por: Kroll, Michael H., et al.
Publicado: (2022)

Rheumatic complications in cancer patients treated with immune checkpoint inhibitors
por: Lee, Kyung-Ann, et al.
Publicado: (2019)

Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
por: Cadranel, Jacques, et al.
Publicado: (2019)

Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review
por: Yu, Caberry W, et al.
Publicado: (2020)

Hypoparathyroidism: An Uncommon Complication Associated With Immune Checkpoint Inhibitor Therapy
por: El Kawkgi, Omar M., et al.
Publicado: (2020)

Mechanism of resistance to immune checkpoint inhibitors
por: Pandey, Manu R., et al.
Publicado: (2019)

Prevention of venous thromboembolism in ambulatory patients with cancer
por: Khorana, Alok A, et al.
Publicado: (2020)

Pulmonary Complications Secondary to Immune Checkpoint Inhibitors
por: Albitar, Hasan Ahmad Hasan, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists
por: Pacholczak-Madej, Renata, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Therapy Associated Hypophysitis
por: Mahzari, Moeber, et al.
Publicado: (2015)

COVID-19 Associated Coagulopathy and Thrombotic Complications
por: Mezalek, Zoubida Tazi, et al.
Publicado: (2020)

Immune Checkpoints Contribute Corneal Immune Privilege: Implications for Dry Eye Associated with Checkpoint Inhibitors
por: Hori, Junko, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Associated Thrombotic Thrombocytopenic Purpura in a Patient With Metastatic Non-Small-Cell Lung Cancer
por: De Filippis, Samantha, et al.
Publicado: (2021)

Immune-Checkpoint Inhibitors in B-Cell Lymphoma
por: Armengol, Marc, et al.
Publicado: (2021)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

Immune checkpoint inhibitors in the treatment of virus-associated cancers
por: Gao, Peipei, et al.
Publicado: (2019)

Management of pulmonary toxicity associated with immune checkpoint inhibitors
por: Delaunay, Myriam, et al.
Publicado: (2019)

Mechanisms of resistance to immune checkpoint inhibitors
por: Jenkins, Russell W, et al.
Publicado: (2018)

Persistence of Platelets Activation Prior to Second Doses of Covid-19 Vaccine After Vaccine-Induced Immune Thrombotic Thrombocytopenia
por: Roberge, Guillaume, et al.
Publicado: (2022)

Toxicities associated with immune checkpoint inhibitors: a systematic study
por: Kong, Xiangyi, et al.
Publicado: (2023)

Biomarkers for predicting the efficacy of immune checkpoint inhibitors
por: Wang, Chengji, et al.
Publicado: (2022)

Infectious complications of immune checkpoint inhibitors in solid organ malignancies
por: Ross, Justine Abella, et al.
Publicado: (2021)

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Spallarossa, Paolo, et al.
Publicado: (2020)

Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system
por: Dalakas, Marinos C.
Publicado: (2018)

Immune Checkpoint Inhibitors in Prostate Cancer
por: Venkatachalam, Shobi, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Special Populations
por: Shan, Qianyun, et al.
Publicado: (2021)

Immune checkpoint inhibitors in clinical trials
por: Sharon, Elad, et al.
Publicado: (2014)

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Cardiotoxicity from immune checkpoint inhibitors
por: Michel, Lars, et al.
Publicado: (2019)

The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
por: Nardi Agmon, Inbar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b45efd1gcfoamgp9akhr9o5t3i